🟢 SAB Biotherapeutics is trading 7.61% up in pre-market with no confirmed catalyst

SAB Biotherapeutics is trading at $3.11, up 7.61%, in pre-market, with no fresh company-specific announcement identified to explain the gain.

• The company announced October 1 that it would present SAB-142 Phase 1 data at the October 9–11 Breakthrough T1D Congress. Presentations are scheduled for October 10, making this known event context rather than a confirmed new catalyst.
• Major U.S. futures were higher, but available evidence does not establish that broader-market sentiment drove the move.